{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:54:11Z","timestamp":1780649651443,"version":"3.54.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pituitary hormones play a crucial role in regulating skeletal physiology, and skeletal fragility is a frequent complication of pituitary diseases. The ability to predict the risk of fracture events is crucial for guiding therapeutic decisions; however, in patients with pituitary diseases, fracture risk estimation is particularly challenging. Compared to primary osteoporosis, the evaluation of bone mineral density by dual X-ray absorptiometry is much less informative about fracture risk. Moreover, the reliability of standard fracture risk calculators does not have strong validations in this setting. Morphometric vertebral assessment is currently the cornerstone in the assessment of skeletal fragility in patients with pituitary diseases, as prevalent fractures remain the strongest predictor of future fracture events. In recent years, new tools for evaluating bone quality have shown promising results in assessing bone impairment in patients with pituitary diseases, but most available data are cross-sectional, and evidence regarding the prediction of incident fractures is still scarce. Of note, apart from measures of bone density and bone quality, the estimation of fracture risk in the context of pituitary hyperfunction or hypofunction cannot ignore the evaluation of factors related to the underlying disease, such as its severity and duration, as well as the specific therapies implemented for its treatment. Aim of this review is to provide an up-to-date overview of all major evidence regarding fracture risk prediction in patients with pituitary disease, highlighting the need for a tailored approach that critically integrates all clinical, biochemical, and instrumental data according to the specificities of each disease.<\/jats:p>","DOI":"10.1007\/s11102-024-01447-3","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:02:05Z","timestamp":1725602525000},"page":"789-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Skeletal fragility in pituitary disease: how can we predict fracture risk?"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-7023","authenticated-orcid":false,"given":"Fabio","family":"Bioletto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Maria","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Barale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Simone","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Sauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mocellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Sagone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"1447_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/ER.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and Bone. Endocr Rev 39:440\u2013488. https:\/\/doi.org\/10.1210\/ER.2018-00005","journal-title":"Endocr Rev"},{"key":"1447_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrendo.2014.125","volume":"10","author":"SE Sattui","year":"2014","unstructured":"Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592\u2013602. https:\/\/doi.org\/10.1038\/nrendo.2014.125","journal-title":"Nat Rev Endocrinol"},{"key":"1447_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of Postmenopausal osteoporosis \u2013\u20092020 Update. Endocr Pract 26:1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"key":"1447_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581\u2013589. https:\/\/doi.org\/10.1007\/s00198-004-1780-5","journal-title":"Osteoporos Int"},{"key":"1447_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4:368\u2013381. https:\/\/doi.org\/10.1007\/BF01622200","journal-title":"Osteoporos Int"},{"key":"1447_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A et al (2008) FRAX\u2122 and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397. https:\/\/doi.org\/10.1007\/s00198-007-0543-5","journal-title":"Osteoporos Int"},{"key":"1447_CR7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00198-007-0362-8","volume":"18","author":"ND Nguyen","year":"2007","unstructured":"Nguyen ND, Frost SA, Center JR et al (2007) Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 18:1109\u20131117. https:\/\/doi.org\/10.1007\/s00198-007-0362-8","journal-title":"Osteoporos Int"},{"key":"1447_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1136\/bmj.b4229","volume":"339","author":"J Hippisley-Cox","year":"2009","unstructured":"Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:1291\u20131295. https:\/\/doi.org\/10.1136\/bmj.b4229","journal-title":"BMJ"},{"key":"1447_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling PR, Nguyen HH, Aleksova J et al (2022) Secondary osteoporosis. Endocr Rev 43:240\u2013313. https:\/\/doi.org\/10.1210\/endrev\/bnab028","journal-title":"Endocr Rev"},{"key":"1447_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12020-014-0280-4","volume":"47","author":"FM Ulivieri","year":"2014","unstructured":"Ulivieri FM, Silva BC, Sardanelli F et al (2014) Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine 47:435\u2013448. https:\/\/doi.org\/10.1007\/s12020-014-0280-4","journal-title":"Endocrine"},{"key":"1447_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/JBMR.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J bone Min Res 29:518\u2013530. https:\/\/doi.org\/10.1002\/JBMR.2176","journal-title":"J bone Min Res"},{"key":"1447_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00198-023-06817-4","volume":"34","author":"E Shevroja","year":"2023","unstructured":"Shevroja E, Reginster JY, Lamy O et al (2023) Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Disease. Osteoporos Int 34:1501\u20131529. https:\/\/doi.org\/10.1007\/s00198-023-06817-4","journal-title":"Osteoporos Int"},{"key":"1447_CR13","doi-asserted-by":"publisher","first-page":"100711","DOI":"10.1016\/j.bonr.2020.100711","volume":"13","author":"N Ohs","year":"2020","unstructured":"Ohs N, Collins CJ, Atkins PR (2020) Validation of HR-pQCT against micro-CT for morphometric and biomechanical analyses: a review. Bone Rep 13:100711. https:\/\/doi.org\/10.1016\/j.bonr.2020.100711","journal-title":"Bone Rep"},{"key":"1447_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/jbmr.3901","volume":"35","author":"N Mikolajewicz","year":"2020","unstructured":"Mikolajewicz N, Bishop N, Burghardt AJ et al (2020) HR-pQCT measures of bone microarchitecture predict fracture: systematic review and Meta-analysis. J Bone Min Res 35:446\u2013459. https:\/\/doi.org\/10.1002\/jbmr.3901","journal-title":"J Bone Min Res"},{"key":"1447_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000528199","volume":"113","author":"F Bioletto","year":"2023","unstructured":"Bioletto F, Barale M, Prencipe N et al (2023) Trabecular bone score as an index of bone fragility in patients with acromegaly: a systematic review and meta-analysis. Neuroendocrinology 113:395\u2013405. https:\/\/doi.org\/10.1159\/000528199","journal-title":"Neuroendocrinology"},{"key":"1447_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1234237","author":"F Bioletto","year":"2023","unstructured":"Bioletto F, Barale M, Parasiliti-Caprino M et al (2023) Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2023.1234237","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1447_CR17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad724","author":"F Bioletto","year":"2023","unstructured":"Bioletto F, Barale M, Maiorino F et al (2023) Trabecular bone score as a marker of skeletal fragility across the spectrum of chronic kidney disease: a systematic review and meta-analysis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad724","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae234","author":"F Bioletto","year":"2024","unstructured":"Bioletto F, Sibilla M, Berton AM et al (2024) Mild hyponatremia is not associated with degradation of trabecular bone microarchitecture despite bone mass loss. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae234","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR19","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1210\/jc.2012-4255","volume":"98","author":"BC Silva","year":"2013","unstructured":"Silva BC, Boutroy S, Zhang C et al (2013) Trabecular bone score (TBS)-A novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98:1963\u20131970. https:\/\/doi.org\/10.1210\/jc.2012-4255","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/cen.13743","volume":"89","author":"H Vinolas","year":"2018","unstructured":"Vinolas H, Grouthier V, Mehsen-Cetre N et al (2018) Assessment of vertebral microarchitecture in overt and mild Cushing\u2019s syndrome using trabecular bone score. Clin Endocrinol (Oxf) 89:148\u2013154. https:\/\/doi.org\/10.1111\/cen.13743","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1447_CR21","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00198-019-05053-z","volume":"30","author":"LT Ho-Pham","year":"2019","unstructured":"Ho-Pham LT, Nguyen TV (2019) Association between trabecular bone score and type 2 diabetes: a quantitative update of evidence. Osteoporos Int 30:2079\u20132085. https:\/\/doi.org\/10.1007\/s00198-019-05053-z","journal-title":"Osteoporos Int"},{"key":"1447_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","volume":"44","author":"M Schini","year":"2023","unstructured":"Schini M, Vilaca T, Gossiel F et al (2023) Bone turnover markers: Basic Biology to Clinical Applications. Endocr Rev 44:417\u2013473. https:\/\/doi.org\/10.1210\/endrev\/bnac031","journal-title":"Endocr Rev"},{"key":"1447_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2022.09.002","volume":"109\u2013110","author":"JP Brown","year":"2022","unstructured":"Brown JP, Don-Wauchope A, Douville P et al (2022) Current use of bone turnover markers in the management of osteoporosis. Clin Biochem 109\u2013110:1\u201310. https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.09.002","journal-title":"Clin Biochem"},{"key":"1447_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1210\/ER.2007-0036","volume":"29","author":"A Giustina","year":"2008","unstructured":"Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535\u2013559. https:\/\/doi.org\/10.1210\/ER.2007-0036","journal-title":"Endocr Rev"},{"key":"1447_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm12010164","volume":"12","author":"MC Sorohan","year":"2023","unstructured":"Sorohan MC, Poiana C (2023) Vertebral fractures in Acromegaly: a systematic review. J Clin Med 12:1\u201317. https:\/\/doi.org\/10.3390\/jcm12010164","journal-title":"J Clin Med"},{"key":"1447_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1210\/jc.2014-2937","volume":"100","author":"G Mazziotti","year":"2015","unstructured":"Mazziotti G, Biagioli E, Maffezzoni F et al (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100:384\u2013394. https:\/\/doi.org\/10.1210\/jc.2014-2937","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR27","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1210\/JC.2013-1460","volume":"98","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Bianchi A, Porcelli T et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402\u20133410. https:\/\/doi.org\/10.1210\/JC.2013-1460","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3803\/ENM.2023.601","volume":"38","author":"A Giustina","year":"2023","unstructured":"Giustina A (2023) Acromegaly and bone: an update. Endocrinol Metab 38:655\u2013666. https:\/\/doi.org\/10.3803\/ENM.2023.601","journal-title":"Endocrinol Metab"},{"key":"1447_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11102-022-01266-4","volume":"25","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Giampietro A, Gagliardi I et al (2022) Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 25:831\u2013841. https:\/\/doi.org\/10.1007\/s11102-022-01266-4","journal-title":"Pituitary"},{"key":"1447_CR30","doi-asserted-by":"crossref","unstructured":"Frara S, Melin Uygur M, di Filippo L et al (2022) High prevalence of vertebral fractures Associated with preoperative GH levels in patients with recent diagnosis of Acromegaly. J Clin Endocrinol Metab","DOI":"10.1210\/clinem\/dgac183"},{"key":"1447_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","volume":"21","author":"S Chiloiro","year":"2018","unstructured":"Chiloiro S, Mazziotti G, Giampietro A et al (2018) Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary 21:302\u2013308. https:\/\/doi.org\/10.1007\/s11102-018-0873-7","journal-title":"Pituitary"},{"key":"1447_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1210\/clinem\/dgz054","volume":"105","author":"S Chiloiro","year":"2020","unstructured":"Chiloiro S, Giampietro A, Frara S et al (2020) Effects of Pegvisomant and Pasireotide LAR on Vertebral fractures in Acromegaly resistant to first-generation SRLs. J Clin Endocrinol Metab 105:87\u201394. https:\/\/doi.org\/10.1210\/clinem\/dgz054","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR33","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1359\/JBMR.050603","volume":"20","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, Mazziotti G, Nuzzo M et al (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Min Res 20:1837\u20131844. https:\/\/doi.org\/10.1359\/JBMR.050603","journal-title":"J Bone Min Res"},{"key":"1447_CR34","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1210\/JC.2012-4073","volume":"98","author":"M Madeira","year":"2013","unstructured":"Madeira M, Neto LV, De Paula Paranhos Neto F et al (2013) Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 98:1734\u20131741. https:\/\/doi.org\/10.1210\/JC.2012-4073","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1530\/EJE-17-0468","volume":"177","author":"PPB Silva","year":"2017","unstructured":"Silva PPB, Amlashi FG, Yu EW et al (2017) Bone microarchitecture and estimated bone strength in men with active acromegaly. Eur J Endocrinol 177:409\u2013420. https:\/\/doi.org\/10.1530\/EJE-17-0468","journal-title":"Eur J Endocrinol"},{"key":"1447_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/EJE-16-0808","volume":"176","author":"F Malgo","year":"2017","unstructured":"Malgo F, Hamdy NAT, Rabelink TJ et al (2017) Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. Eur J Endocrinol 176:339\u2013347. https:\/\/doi.org\/10.1530\/EJE-16-0808","journal-title":"Eur J Endocrinol"},{"key":"1447_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1530\/EJE-18-0881","volume":"180","author":"M Ku\u017ema","year":"2019","unstructured":"Ku\u017ema M, Va\u0148uga P, S\u00e1gova I et al (2019) Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol 180:201\u2013211. https:\/\/doi.org\/10.1530\/EJE-18-0881","journal-title":"Eur J Endocrinol"},{"key":"1447_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s001980200030","volume":"13","author":"M Bolanowski","year":"2002","unstructured":"Bolanowski M, J\u0229drzejuk D, Milewicz A, Arkowska A (2002) Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporos Int 13:303\u2013308. https:\/\/doi.org\/10.1007\/s001980200030","journal-title":"Osteoporos Int"},{"key":"1447_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jocd.2007.03.103","volume":"10","author":"D Kastelan","year":"2007","unstructured":"Kastelan D, Dusek T, Kraljevic I et al (2007) Bone properties in patients with acromegaly: quantitative ultrasound of the heel. J Clin Densitom 10:327\u2013331. https:\/\/doi.org\/10.1016\/j.jocd.2007.03.103","journal-title":"J Clin Densitom"},{"key":"1447_CR40","doi-asserted-by":"publisher","first-page":"E3285","DOI":"10.1210\/CLINEM\/DGAA363","volume":"105","author":"G Mazziotti","year":"2020","unstructured":"Mazziotti G, Battista C, Maffezzoni F et al (2020) Treatment of Acromegalic Osteopathy in Real-life clinical practice: the BAAC (bone active drugs in acromegaly) study. J Clin Endocrinol Metab 105:E3285\u2013E3292. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA363","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR41","doi-asserted-by":"publisher","first-page":"E937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105:E937\u2013E946. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tem.2023.01.006","volume":"34","author":"MM Uygur","year":"2023","unstructured":"Uygur MM, Frara S, di Filippo L, Giustina A (2023) New tools for bone health assessment in secreting pituitary adenomas. Trends Endocrinol Metab 34:231\u2013242. https:\/\/doi.org\/10.1016\/j.tem.2023.01.006","journal-title":"Trends Endocrinol Metab"},{"key":"1447_CR43","doi-asserted-by":"publisher","first-page":"E58","DOI":"10.1210\/clinem\/dgad493","volume":"109","author":"S Chiloiro","year":"2024","unstructured":"Chiloiro S, Frara S, Gagliardi I et al (2024) Cholecalciferol Use is Associated with a decreased risk of incident morphometric vertebral fractures in Acromegaly. J Clin Endocrinol Metab 109:E58\u2013E68. https:\/\/doi.org\/10.1210\/clinem\/dgad493","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR44","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s12020-021-02751-9","volume":"73","author":"MM Uygur","year":"2021","unstructured":"Uygur MM, Yaz\u0131c\u0131 DD, Bu\u011fdayc\u0131 O, Yavuz DG (2021) Prevalence of vertebral fractures and serum sclerostin levels in acromegaly. Endocrine 73:667\u2013673. https:\/\/doi.org\/10.1007\/s12020-021-02751-9","journal-title":"Endocrine"},{"key":"1447_CR45","doi-asserted-by":"publisher","unstructured":"Sala E, Malchiodi E, Carosi G et al (2021) Spine bone texture assessed by trabecular bone score in active and controlled acromegaly: a prospective study. J Endocr Soc 5. https:\/\/doi.org\/10.1210\/JENDSO\/BVAB090","DOI":"10.1210\/JENDSO\/BVAB090"},{"key":"1447_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/EJE-16-0340","volume":"175","author":"K Godang","year":"2016","unstructured":"Godang K, Olarescu NC, Bollerslev J, Heck A (2016) Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur J Endocrinol 175:155\u2013164. https:\/\/doi.org\/10.1530\/EJE-16-0340","journal-title":"Eur J Endocrinol"},{"key":"1447_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000443866","volume":"46","author":"G Mazziotti","year":"2016","unstructured":"Mazziotti G, Delgado A, Maffezzoni F et al (2016) Skeletal fragility in endogenous hypercortisolism. Front Horm Res 46:66\u201373. https:\/\/doi.org\/10.1159\/000443866","journal-title":"Front Horm Res"},{"key":"1447_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11102-005-1051-2","volume":"7","author":"T Mancini","year":"2004","unstructured":"Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing\u2019s syndrome and bone. Pituitary 7:249\u2013252. https:\/\/doi.org\/10.1007\/s11102-005-1051-2","journal-title":"Pituitary"},{"key":"1447_CR49","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1210\/jc.83.6.1863","volume":"83","author":"I Chiodini","year":"1998","unstructured":"Chiodini I, Carnevale V, Torlontano M et al (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 83:1863\u20131867. https:\/\/doi.org\/10.1210\/jc.83.6.1863","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR50","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319\u20131328. https:\/\/doi.org\/10.1007\/s00198-007-0394-0","journal-title":"Osteoporos Int"},{"key":"1447_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/eje.0.1460051","volume":"146","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Lindholm J, J\u00f8rgensen JOL et al (2002) Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome. Eur J Endocrinol 146:51\u201356. https:\/\/doi.org\/10.1530\/eje.0.1460051","journal-title":"Eur J Endocrinol"},{"key":"1447_CR52","doi-asserted-by":"publisher","unstructured":"Sun H, Wu C, Hu B, Xie G (2023) High prevalence of vertebral fractures associated with preoperative cortisol levels in patients with recent diagnosis of cushing disease. Ann Med 55. https:\/\/doi.org\/10.1080\/07853890.2023.2282183","DOI":"10.1080\/07853890.2023.2282183"},{"key":"1447_CR53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","volume":"25","author":"L Trementino","year":"2014","unstructured":"Trementino L, Appolloni G, Ceccoli L et al (2014) Bone complications in patients with Cushing\u2019s syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int 25:913\u2013921. https:\/\/doi.org\/10.1007\/s00198-013-2520-5","journal-title":"Osteoporos Int"},{"key":"1447_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-015-0244-1","volume":"10","author":"ZE Belaya","year":"2015","unstructured":"Belaya ZE, Hans D, Rozhinskaya LY et al (2015) The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing\u2019s syndrome. Arch Osteoporos 10:1\u20139. https:\/\/doi.org\/10.1007\/s11657-015-0244-1","journal-title":"Arch Osteoporos"},{"key":"1447_CR55","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/EJE-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"Valassi E, Santos A, Yaneva M et al (2011) The European Registry on Cushing\u2019s syndrome: 2-Year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165:383\u2013392. https:\/\/doi.org\/10.1530\/EJE-11-0272","journal-title":"Eur J Endocrinol"},{"key":"1447_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11102-011-0306-3","volume":"15","author":"ME Randazzo","year":"2012","unstructured":"Randazzo ME, Grossrubatscher E, Ciaramella PD et al (2012) Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 15:193\u2013201. https:\/\/doi.org\/10.1007\/s11102-011-0306-3","journal-title":"Pituitary"},{"key":"1447_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.beem.2021.101515","volume":"35","author":"S Frara","year":"2021","unstructured":"Frara S, Allora A, Di Filippo L et al (2021) Osteopathy in mild adrenal Cushing\u2019s syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab 35:19. https:\/\/doi.org\/10.1016\/j.beem.2021.101515","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1447_CR58","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40618-014-0126-1","volume":"37","author":"L Trementino","year":"2014","unstructured":"Trementino L, Ceccoli L, Concettoni C et al (2014) Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX\u00ae algorithm useful? J Endocrinol Invest 37:957\u2013965. https:\/\/doi.org\/10.1007\/s40618-014-0126-1","journal-title":"J Endocrinol Invest"},{"key":"1447_CR59","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1210\/jc.2005-0582","volume":"91","author":"L Tauchmanov\u00e0","year":"2006","unstructured":"Tauchmanov\u00e0 L, Pivonello R, Di Somma C et al (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91:1779\u20131784. https:\/\/doi.org\/10.1210\/jc.2005-0582","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR60","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s40618-020-01496-y","volume":"44","author":"T Apayd\u0131n","year":"2021","unstructured":"Apayd\u0131n T, Yavuz DG (2021) Assessment of non-traumatic vertebral fractures in Cushing\u2019s syndrome patients. J Endocrinol Invest 44:1767\u20131773. https:\/\/doi.org\/10.1007\/s40618-020-01496-y","journal-title":"J Endocrinol Invest"},{"key":"1447_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.593173","volume":"11","author":"B Stachowska","year":"2021","unstructured":"Stachowska B, Halupczok-\u017by\u0142a J, Kuliczkowska-P\u0142aksej J et al (2021) Decreased trabecular bone score in patients with active endogenous Cushing\u2019s syndrome. Front Endocrinol (Lausanne) 11:1\u20139. https:\/\/doi.org\/10.3389\/fendo.2020.593173","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1447_CR62","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12020-023-03318-6","volume":"80","author":"F Ferra\u00f9","year":"2023","unstructured":"Ferra\u00f9 F, Giovinazzo S, Alessi Y et al (2023) Trabecular bone score, bone marrow fat and vertebral fractures in cushing syndrome. Endocrine 80:441\u2013447. https:\/\/doi.org\/10.1007\/s12020-023-03318-6","journal-title":"Endocrine"},{"key":"1447_CR63","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/cen.12812","volume":"83","author":"CV Dos Santos","year":"2015","unstructured":"Dos Santos CV, Vieira Neto L, Madeira M et al (2015) Bone density and microarchitecture in endogenous hypercortisolism. Clin Endocrinol (Oxf) 83:468\u2013474. https:\/\/doi.org\/10.1111\/cen.12812","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1447_CR64","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11102-022-01252-w","volume":"25","author":"S Frara","year":"2022","unstructured":"Frara S, di Filippo L, Doga M et al (2022) Novel approaches to bone comorbidity in Cushing\u2019s disease: an update. Pituitary 25:754\u2013759. https:\/\/doi.org\/10.1007\/s11102-022-01252-w","journal-title":"Pituitary"},{"key":"1447_CR65","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/0300060517725660","volume":"46","author":"W Guo","year":"2018","unstructured":"Guo W, Li F, Zhu C et al (2018) Effect of hypercortisolism on bone mineral density and bone metabolism: a potential protective effect of adrenocorticotropic hormone in patients with Cushing\u2019s disease. J Int Med Res 46:492\u2013503. https:\/\/doi.org\/10.1177\/0300060517725660","journal-title":"J Int Med Res"},{"key":"1447_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bonekey.2016.42","volume":"5","author":"ZE Belaya","year":"2016","unstructured":"Belaya ZE, Iljin AV, Melnichenko GA et al (2016) Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing\u2019s syndrome. Bonekey Rep 5:1\u20136. https:\/\/doi.org\/10.1038\/bonekey.2016.42","journal-title":"Bonekey Rep"},{"key":"1447_CR67","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1046\/j.0300-0664.2001.01454.doc.x","volume":"56","author":"C Di Somma","year":"2002","unstructured":"Di Somma C, Pivonello R, Loche S et al (2002) Severe impairment of bone mass and turnover in Cushing\u2019s disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol (Oxf) 56:153\u2013158. https:\/\/doi.org\/10.1046\/j.0300-0664.2001.01454.doc.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1447_CR68","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11102-020-01041-3","volume":"23","author":"L di Filippo","year":"2020","unstructured":"di Filippo L, Doga M, Resmini E, Giustina A (2020) Hyperprolactinemia and bone. Pituitary 23:314\u2013321. https:\/\/doi.org\/10.1007\/s11102-020-01041-3","journal-title":"Pituitary"},{"key":"1447_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.0300-0664.2001.01464.x","volume":"56","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, J\u00f8rgensen JOL, Hagen C et al (2002) Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. Clin Endocrinol (Oxf) 56:159\u2013167. https:\/\/doi.org\/10.1046\/j.0300-0664.2001.01464.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1447_CR70","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","volume":"14","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Mancini T, Mormando M et al (2011) High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14:299\u2013306. https:\/\/doi.org\/10.1007\/s11102-011-0293-4","journal-title":"Pituitary"},{"key":"1447_CR71","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","volume":"39","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Mormando M et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39:288\u2013293. https:\/\/doi.org\/10.1007\/s12020-011-9462-5","journal-title":"Endocrine"},{"key":"1447_CR72","doi-asserted-by":"publisher","unstructured":"Nagendra L, Dutta D, Mondal S et al (2024) Hyperprolactinemia due to Prolactinoma has an adverse impact on Bone Health with predominant impact on trabecular bone: a systematic review and Meta-analysis. J Clin Densitom 27. https:\/\/doi.org\/10.1016\/j.jocd.2023.101453","DOI":"10.1016\/j.jocd.2023.101453"},{"key":"1447_CR73","first-page":"745","volume":"36","author":"C D\u2019Sylva","year":"2015","unstructured":"D\u2019Sylva C, Khan T, Van Uum S, Fraser L-A (2015) Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: a systematic review and meta-analysis. Neuro Endocrinol Lett 36:745\u2013749","journal-title":"Neuro Endocrinol Lett"},{"key":"1447_CR74","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","volume":"83","author":"C Di Somma","year":"1998","unstructured":"Di Somma C, Colao A, Di Sarno A et al (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83:807\u2013813. https:\/\/doi.org\/10.1210\/jcem.83.3.4674","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR75","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","volume":"110","author":"SL Greenspan","year":"1989","unstructured":"Greenspan SL, Oppenheim DS, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526\u2013531. https:\/\/doi.org\/10.7326\/0003-4819-110-7-526","journal-title":"Ann Intern Med"},{"key":"1447_CR76","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJM198608283150903","volume":"315","author":"A Klibanski","year":"1986","unstructured":"Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542\u2013546. https:\/\/doi.org\/10.1056\/NEJM198608283150903","journal-title":"N Engl J Med"},{"key":"1447_CR77","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","volume":"64","author":"J Schlechte","year":"1987","unstructured":"Schlechte J, El-Khoury G, Kathol M, Walkner L (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021\u20131026. https:\/\/doi.org\/10.1210\/jcem-64-5-1021","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR78","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/0003-4819-104-6-777","volume":"104","author":"SL Greenspan","year":"1986","unstructured":"Greenspan SL, Neer RM, Ridgway EC, Klibanski A (1986) Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777\u2013782. https:\/\/doi.org\/10.7326\/0003-4819-104-6-777","journal-title":"Ann Intern Med"},{"key":"1447_CR79","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1210\/jcem-56-6-1120","volume":"56","author":"JA Schlechte","year":"1983","unstructured":"Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56:1120\u20131123. https:\/\/doi.org\/10.1210\/jcem-56-6-1120","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-84606-x","volume":"11","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH et al (2021) Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep 11:1\u20139. https:\/\/doi.org\/10.1038\/s41598-021-84606-x","journal-title":"Sci Rep"},{"key":"1447_CR81","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00198-021-06289-4","volume":"33","author":"L Wang","year":"2022","unstructured":"Wang L, Chen K, Duan L et al (2022) Bone microarchitecture impairment in prolactinoma patients assessed by HR-pQCT. Osteoporos Int 33:1535\u20131544. https:\/\/doi.org\/10.1007\/s00198-021-06289-4","journal-title":"Osteoporos Int"},{"key":"1447_CR82","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/13697137.2020.1767567","volume":"23","author":"I Ilovayskaya","year":"2020","unstructured":"Ilovayskaya I, Zektser V, Lazebnik L (2020) Factors of mineral homeostasis impairment and bone mineral density loss in women with central hypogonadism. Climacteric 23:597\u2013602. https:\/\/doi.org\/10.1080\/13697137.2020.1767567","journal-title":"Climacteric"},{"key":"1447_CR83","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.eprac.2021.05.004","volume":"27","author":"R Zhang","year":"2021","unstructured":"Zhang R, Mao J, Wang X et al (2021) Increased bone Mineral density in male patients with idiopathic hypogonadotropic hypogonadism who undergo sex hormone therapy: findings from cross-sectional and longitudinal studies. Endocr Pract 27:934\u2013940. https:\/\/doi.org\/10.1016\/j.eprac.2021.05.004","journal-title":"Endocr Pract"},{"key":"1447_CR84","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2605.2011.01237.x","volume":"35","author":"EM Laitinen","year":"2012","unstructured":"Laitinen EM, Hero M, Vaaralahti K et al (2012) Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism. Int J Androl 35:534\u2013540. https:\/\/doi.org\/10.1111\/j.1365-2605.2011.01237.x","journal-title":"Int J Androl"},{"key":"1447_CR85","doi-asserted-by":"publisher","first-page":"E3312","DOI":"10.1210\/clinem\/dgab169","volume":"106","author":"A Ostertag","year":"2021","unstructured":"Ostertag A, Papadakis GE, Collet C et al (2021) Compromised volumetric bone density and microarchitecture in men with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 106:E3312\u2013E3326. https:\/\/doi.org\/10.1210\/clinem\/dgab169","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0303-7207(99)00223-3","volume":"161","author":"D Canale","year":"2000","unstructured":"Canale D, Vignali E, Golia F et al (2000) Effects of hormonal replacement treatment on bone mineral density and metabolism in hypogonadal patients. Mol Cell Endocrinol 161:47\u201351. https:\/\/doi.org\/10.1016\/S0303-7207(99)00223-3","journal-title":"Mol Cell Endocrinol"},{"key":"1447_CR87","first-page":"117","volume":"4","author":"K Ishizaka","year":"2002","unstructured":"Ishizaka K, Suzuki M, Kageyama Y et al (2002) Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. Asian J Androl 4:117\u2013121","journal-title":"Asian J Androl"},{"key":"1447_CR88","doi-asserted-by":"publisher","first-page":"111052","DOI":"10.1016\/j.mce.2020.111052","volume":"519","author":"M Dixit","year":"2021","unstructured":"Dixit M, Poudel SB, Yakar S (2021) Effects of GH\/IGF axis on bone and cartilage. Mol Cell Endocrinol 519:111052. https:\/\/doi.org\/10.1016\/j.mce.2020.111052","journal-title":"Mol Cell Endocrinol"},{"key":"1447_CR89","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ghir.2017.02.002","volume":"33","author":"A Ciresi","year":"2017","unstructured":"Ciresi A, Giordano C (2017) Vitamin D across growth hormone (GH) disorders: from GH deficiency to GH excess. Growth Horm IGF Res 33:35\u201342. https:\/\/doi.org\/10.1016\/j.ghir.2017.02.002","journal-title":"Growth Horm IGF Res"},{"key":"1447_CR90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/BF02555871","volume":"48","author":"HK Nielsen","year":"1991","unstructured":"Nielsen HK, J\u00f8rgensen JO, Brixen K, Christiansen JS (1991) Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: dose-response studies with biosynthetic human GH. Calcif Tissue Int 48:82\u201387. https:\/\/doi.org\/10.1007\/BF02555871","journal-title":"Calcif Tissue Int"},{"key":"1447_CR91","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/BF03348952","volume":"16","author":"A Sartorio","year":"1993","unstructured":"Sartorio A, Conti A, Monzani M et al (1993) Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover. J Endocrinol Invest 16:893\u2013898. https:\/\/doi.org\/10.1007\/BF03348952","journal-title":"J Endocrinol Invest"},{"key":"1447_CR92","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S8756-3282(02)00952-3","volume":"32","author":"AM Ahmad","year":"2003","unstructured":"Ahmad AM, Hopkins MT, Fraser WD et al (2003) Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 32:170\u2013179. https:\/\/doi.org\/10.1016\/S8756-3282(02)00952-3","journal-title":"Bone"},{"key":"1447_CR93","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1359\/jbmr.060112","volume":"21","author":"G Mazziotti","year":"2006","unstructured":"Mazziotti G, Bianchi A, Bonadonna S et al (2006) Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Min Res 21:520\u2013528. https:\/\/doi.org\/10.1359\/jbmr.060112","journal-title":"J Bone Min Res"},{"key":"1447_CR94","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1530\/eje.0.1370240","volume":"137","author":"T Ros\u00e9n","year":"1997","unstructured":"Ros\u00e9n T, Wilhelmsen L, Landin-Wilhelmsen K et al (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240\u2013245. https:\/\/doi.org\/10.1530\/eje.0.1370240","journal-title":"Eur J Endocrinol"},{"key":"1447_CR95","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1359\/jbmr.2001.16.2.398","volume":"16","author":"C W\u00fcster","year":"2001","unstructured":"W\u00fcster C, Abs R, Bengtsson B\u00c5 et al (2001) The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Min Res 16:398\u2013405. https:\/\/doi.org\/10.1359\/jbmr.2001.16.2.398","journal-title":"J Bone Min Res"},{"key":"1447_CR96","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1210\/jc.2004-0054","volume":"89","author":"R Bouillon","year":"2004","unstructured":"Bouillon R, Koledova E, Bezlepkina O et al (2004) Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 89:4993\u20134998. https:\/\/doi.org\/10.1210\/jc.2004-0054","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR97","doi-asserted-by":"publisher","unstructured":"Akirov A, Rudman Y, Fleseriu M (2024) Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes. https:\/\/doi.org\/10.1007\/s11102-024-01391-2. Pituitary","DOI":"10.1007\/s11102-024-01391-2"},{"key":"1447_CR98","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","volume":"52","author":"G Mazziotti","year":"2016","unstructured":"Mazziotti G, Doga M, Frara S et al (2016) Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52:103\u2013110. https:\/\/doi.org\/10.1007\/s12020-015-0738-z","journal-title":"Endocrine"},{"key":"1447_CR99","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09878-w","author":"J Kuliczkowska-P\u0142aksej","year":"2024","unstructured":"Kuliczkowska-P\u0142aksej J, Zdrojowy-We\u0142na A, Jawiarczyk-Przyby\u0142owska A et al (2024) Diagnosis and therapeutic approach to bone health in patients with hypopituitarism. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-024-09878-w","journal-title":"Rev Endocr Metab Disord"},{"key":"1447_CR100","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S2213-8587(15)00098-4","volume":"3","author":"D Mo","year":"2015","unstructured":"Mo D, Fleseriu M, Qi R et al (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3:331\u2013338. https:\/\/doi.org\/10.1016\/S2213-8587(15)00098-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1447_CR101","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1210\/jcem.78.3.8126140","volume":"78","author":"SJ Holmes","year":"1994","unstructured":"Holmes SJ, Economou G, Whitehouse RW et al (1994) Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 78:669\u2013674. https:\/\/doi.org\/10.1210\/jcem.78.3.8126140","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR102","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1210\/jc.2010-2662","volume":"96","author":"NA Tritos","year":"2011","unstructured":"Tritos NA, Greenspan SL, King D et al (2011) Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. J Clin Endocrinol Metab 96:1516\u20131523. https:\/\/doi.org\/10.1210\/jc.2010-2662","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR103","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1359\/jbmr.2002.17.6.1081","volume":"17","author":"M Bex","year":"2002","unstructured":"Bex M, Abs R, Maiter D et al (2002) The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Min Res 17:1081\u20131094. https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1081","journal-title":"J Bone Min Res"},{"key":"1447_CR104","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2265.2003.01949.x","volume":"60","author":"GI Baroncelli","year":"2004","unstructured":"Baroncelli GI, Bertelloni S, Sodini F, Saggese G (2004) Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf) 60:175\u2013184. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01949.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1447_CR105","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1210\/jc.2005-0208","volume":"90","author":"N Mauras","year":"2005","unstructured":"Mauras N, Pescovitz OH, Allada V et al (2005) Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 90:3946\u20133955. https:\/\/doi.org\/10.1210\/jc.2005-0208","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"1447_CR106","first-page":"82","volume":"4","author":"R Rapaport","year":"2006","unstructured":"Rapaport R, Cook DM (2006) Transition of childhood-onset growth hormone-deficient patients to adult healthcare. Pediatr Endocrinol Rev 4(Suppl 1):82\u201390","journal-title":"Pediatr Endocrinol Rev"},{"key":"1447_CR107","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1210\/jc.2007-0167","volume":"92","author":"S Radovick","year":"2007","unstructured":"Radovick S, DiVall S (2007) Approach to the patient: Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 92:1195\u20131200. https:\/\/doi.org\/10.1210\/jc.2007-0167","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR108","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1210\/jc.82.5.1462","volume":"82","author":"AA Toogood","year":"1997","unstructured":"Toogood AA, Adams JE, O\u2019Neill PA, Shalet SM (1997) Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 82:1462\u20131466. https:\/\/doi.org\/10.1210\/jc.82.5.1462","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR109","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1530\/acta.0.1290201","volume":"129","author":"T Ros\u00e9n","year":"1993","unstructured":"Ros\u00e9n T, Hansson T, Granhed H et al (1993) Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129:201\u2013206. https:\/\/doi.org\/10.1530\/acta.0.1290201","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1447_CR110","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1210\/jc.2003-030685","volume":"89","author":"RD Murray","year":"2004","unstructured":"Murray RD, Columb B, Adams JE, Shalet SM (2004) Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 89:1124\u20131130. https:\/\/doi.org\/10.1210\/jc.2003-030685","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR111","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1359\/JBMR.050613","volume":"20","author":"N Bravenboer","year":"2005","unstructured":"Bravenboer N, Holzmann PJ, Ter Maaten JC et al (2005) Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Min Res 20:1778\u20131784. https:\/\/doi.org\/10.1359\/JBMR.050613","journal-title":"J Bone Min Res"},{"key":"1447_CR112","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/EJE-18-0711","volume":"180","author":"H Yang","year":"2019","unstructured":"Yang H, Yan K, Xu Y et al (2019) Bone microarchitecture and volumetric bone density impairment in young male adults with childhood-onset growth hormone deficiency. Eur J Endocrinol 180:145\u2013153. https:\/\/doi.org\/10.1530\/EJE-18-0711","journal-title":"Eur J Endocrinol"},{"key":"1447_CR113","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4158\/EP151183.OR","volume":"22","author":"M Ku\u017ema","year":"2016","unstructured":"Ku\u017ema M, Binkley N, Bedn\u00e1rov\u00e1 A et al (2016) Trabecular bone score change differs with regard to 25(OH)D levels in patients treated for adult-onset growth hormone Deficiency. Endocr Pract 22:951\u2013958. https:\/\/doi.org\/10.4158\/EP151183.OR","journal-title":"Endocr Pract"},{"key":"1447_CR114","doi-asserted-by":"publisher","first-page":"61","DOI":"10.33549\/PHYSIOLRES.934775","volume":"70","author":"P Va\u0148uga","year":"2021","unstructured":"Va\u0148uga P, Ku\u017ema M, Stojkovi\u010dov\u00e1 D et al (2021) The Long-Term effects of growth hormone replacement on bone Mineral density and trabecular bone score: results of the 10-Year prospective follow-up. Physiol Res 70:61\u201368. https:\/\/doi.org\/10.33549\/PHYSIOLRES.934775","journal-title":"Physiol Res"},{"key":"1447_CR115","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/2042018816643908","volume":"7","author":"G Allo Miguel","year":"2016","unstructured":"Allo Miguel G, Serraclara Pl\u00e1 A, Partida Mu\u00f1oz ML et al (2016) Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center. Ther Adv Endocrinol Metab 7:93\u2013100. https:\/\/doi.org\/10.1177\/2042018816643908","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1447_CR116","doi-asserted-by":"publisher","unstructured":"Ku\u017ema M, Killinger Z, Jackuliak P et al (2019) Pathophysiology of growth hormone secretion disorders and their impact on bone microstructure as measured by trabecular bone score. Physiol Res 68. https:\/\/doi.org\/10.33549\/PHYSIOLRES.934303","DOI":"10.33549\/PHYSIOLRES.934303"},{"key":"1447_CR117","doi-asserted-by":"publisher","first-page":"R231","DOI":"10.1530\/EJE-17-0154","volume":"177","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Formenti AM, Frara S et al (2017) Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 177:R231\u2013R248. https:\/\/doi.org\/10.1530\/EJE-17-0154","journal-title":"Eur J Endocrinol"},{"key":"1447_CR118","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/EJE-10-0125","volume":"163","author":"G Mazziotti","year":"2010","unstructured":"Mazziotti G, Porcelli T, Bianchi A et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15\u201320. https:\/\/doi.org\/10.1530\/EJE-10-0125","journal-title":"Eur J Endocrinol"},{"key":"1447_CR119","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrendo.2013.5","volume":"9","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9:265\u2013276. https:\/\/doi.org\/10.1038\/nrendo.2013.5","journal-title":"Nat Rev Endocrinol"},{"key":"1447_CR120","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1210\/jc.2003-030286","volume":"88","author":"DJ Wake","year":"2003","unstructured":"Wake DJ, Rask E, Livingstone DEW et al (2003) Local and systemic impact of transcriptional up-regulation of 11\u03b2-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:3983\u20133988. https:\/\/doi.org\/10.1210\/jc.2003-030286","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR121","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1530\/EJE-13-0596","volume":"170","author":"LA Behan","year":"2014","unstructured":"Behan LA, Kelleher G, Hannon MJ et al (2014) Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients. Eur J Endocrinol 170:141\u2013150. https:\/\/doi.org\/10.1530\/EJE-13-0596","journal-title":"Eur J Endocrinol"},{"key":"1447_CR122","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","volume":"120","author":"PM Zelissen","year":"1994","unstructured":"Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA (1994) Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120:207\u2013210. https:\/\/doi.org\/10.7326\/0003-4819-120-3-199402010-00005","journal-title":"Ann Intern Med"},{"key":"1447_CR123","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-15-1096","volume":"174","author":"J Schulz","year":"2016","unstructured":"Schulz J, Frey KR, Cooper MS et al (2016) Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol 174:531\u2013538. https:\/\/doi.org\/10.1530\/EJE-15-1096","journal-title":"Eur J Endocrinol"},{"key":"1447_CR124","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/EJE-08-0880","volume":"160","author":"K L\u00f8vas","year":"2009","unstructured":"L\u00f8vas K, Gjesdal CG, Christensen M et al (2009) Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone. Eur J Endocrinol 160:993\u20131002. https:\/\/doi.org\/10.1530\/EJE-08-0880","journal-title":"Eur J Endocrinol"},{"key":"1447_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-13506-5","volume":"12","author":"V Guarnotta","year":"2022","unstructured":"Guarnotta V, Di Stefano C, Giordano C (2022) Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency. Sci Rep 12:1\u20139. https:\/\/doi.org\/10.1038\/s41598-022-13506-5","journal-title":"Sci Rep"},{"key":"1447_CR126","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12020-017-1512-1","volume":"60","author":"S Frara","year":"2018","unstructured":"Frara S, Chiloiro S, Porcelli T et al (2018) Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60:528\u2013531. https:\/\/doi.org\/10.1007\/s12020-017-1512-1","journal-title":"Endocrine"},{"key":"1447_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvad151","volume":"8","author":"V Hasenmajer","year":"2024","unstructured":"Hasenmajer V, Ferrari D, De Alcubierre D et al (2024) Effects of dual-release hydrocortisone on bone metabolism in primary and secondary adrenal insufficiency: a 6-Year study. J Endocr Soc 8:1\u201310. https:\/\/doi.org\/10.1210\/jendso\/bvad151","journal-title":"J Endocr Soc"},{"key":"1447_CR128","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1210\/me.2007-0157","volume":"21","author":"JHD Bassett","year":"2007","unstructured":"Bassett JHD, Nordstr\u00f6m K, Boyde A et al (2007) Thyroid status during skeletal development determines adult bone structure and mineralization. Mol Endocrinol 21:1893\u20131904. https:\/\/doi.org\/10.1210\/me.2007-0157","journal-title":"Mol Endocrinol"},{"key":"1447_CR129","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1002\/jbmr.432","volume":"26","author":"LE Monfoulet","year":"2011","unstructured":"Monfoulet LE, Rabier B, Dacquin R et al (2011) Thyroid hormone receptor \u03b2 mediates thyroid hormone effects on bone remodeling and bone mass. J Bone Min Res 26:2036\u20132044. https:\/\/doi.org\/10.1002\/jbmr.432","journal-title":"J Bone Min Res"},{"key":"1447_CR130","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1359\/JBMR.041126","volume":"20","author":"G Mazziotti","year":"2005","unstructured":"Mazziotti G, Sorvillo F, Piscopo M et al (2005) Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Min Res 20:480\u2013486. https:\/\/doi.org\/10.1359\/JBMR.041126","journal-title":"J Bone Min Res"},{"key":"1447_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2017.00252","volume":"8","author":"R Baliram","year":"2017","unstructured":"Baliram R, Latif R, Zaidi M, Davies TF (2017) Expanding the role of thyroid-stimulating hormone in skeletal physiology. Front Endocrinol (Lausanne) 8:1\u20139. https:\/\/doi.org\/10.3389\/fendo.2017.00252","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1447_CR132","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/105072503322238854","volume":"13","author":"P Vestergaard","year":"2003","unstructured":"Vestergaard P, Mosekilde L (2003) Hyperthyroidism, bone mineral, and fracture risk - a meta-analysis. Thyroid 13:585\u2013593. https:\/\/doi.org\/10.1089\/105072503322238854","journal-title":"Thyroid"},{"key":"1447_CR133","doi-asserted-by":"publisher","unstructured":"Frara S, Uygur MM, Bolamperti F et al (2024) High prevalence of morphometric vertebral fractures opportunistically detected on thoracic radiograms in patients with non-functioning pituitary adenoma. https:\/\/doi.org\/10.1007\/s11102-024-01394-z. Pituitary","DOI":"10.1007\/s11102-024-01394-z"},{"key":"1447_CR134","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1046\/j.1365-2265.1997.2351057.x","volume":"47","author":"L Persani","year":"1997","unstructured":"Persani L, Preziati D, Matthews CH et al (1997) Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol (Oxf) 47:207\u2013214. https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2351057.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1447_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000002358","volume":"95","author":"AC Mousiolis","year":"2016","unstructured":"Mousiolis AC, Rapti E, Grammatiki M et al (2016) Somatostatin analogue treatment of a TSH-secreting adenoma presenting with accelerated bone metabolism and a pericardial effusion: a case report. Med (United States) 95:1\u20135. https:\/\/doi.org\/10.1097\/MD.0000000000002358","journal-title":"Med (United States)"},{"key":"1447_CR136","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/JC.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:3888\u20133921. https:\/\/doi.org\/10.1210\/JC.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR137","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12020-016-0882-0","volume":"52","author":"AM Formenti","year":"2016","unstructured":"Formenti AM, Mazziotti G, Giubbini R, Giustina A (2016) Treatment of hypothyroidism: all that glitters is gold? Endocrine 52:411\u2013413. https:\/\/doi.org\/10.1007\/s12020-016-0882-0","journal-title":"Endocrine"},{"key":"1447_CR138","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1210\/jcem.81.12.8954028","volume":"81","author":"B Uzzan","year":"1996","unstructured":"Uzzan B, Campos J, Cucherat M et al (1996) Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81:4278\u20134289. https:\/\/doi.org\/10.1210\/jcem.81.12.8954028","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR139","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3109\/00016349609054714","volume":"75","author":"P Affinito","year":"1996","unstructured":"Affinito P, Sorrentino C, Farace MJ et al (1996) Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism. Acta Obstet Gynecol Scand 75:843\u2013848. https:\/\/doi.org\/10.3109\/00016349609054714","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1447_CR140","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1530\/EJE-14-0097","volume":"170","author":"G Mazziotti","year":"2014","unstructured":"Mazziotti G, Mormando M, Cristiano A et al (2014) Association between L-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol 170:893\u2013899. https:\/\/doi.org\/10.1530\/EJE-14-0097","journal-title":"Eur J Endocrinol"},{"key":"1447_CR141","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/01.mnh.0000447022.51722.f4","volume":"23","author":"MJ Hannon","year":"2014","unstructured":"Hannon MJ, Verbalis JG (2014) Sodium homeostasis and bone. Curr Opin Nephrol Hypertens 23:370\u2013376. https:\/\/doi.org\/10.1097\/01.mnh.0000447022.51722.f4","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1447_CR142","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3803\/EnM.2022.1573","volume":"37","author":"SM Kim","year":"2022","unstructured":"Kim SM, Sultana F, Korkmaz F et al (2022) Independent skeletal actions of Pituitary hormones. Endocrinol Metab 37:719\u2013731. https:\/\/doi.org\/10.3803\/EnM.2022.1573","journal-title":"Endocrinol Metab"},{"key":"1447_CR143","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41574-023-00894-5","volume":"19","author":"M Zaidi","year":"2023","unstructured":"Zaidi M, Yuen T, Kim SM (2023) Pituitary crosstalk with bone, adipose tissue and brain. Nat Rev Endocrinol 19:708\u2013721. https:\/\/doi.org\/10.1038\/s41574-023-00894-5","journal-title":"Nat Rev Endocrinol"},{"key":"1447_CR144","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1007\/s00198-017-4163-4","volume":"28","author":"L Wu","year":"2017","unstructured":"Wu L, Luthringer BJC, Feyerabend F et al (2017) Increased levels of sodium chloride directly increase osteoclastic differentiation and resorption in mice and men. Osteoporos Int 28:3215\u20133228. https:\/\/doi.org\/10.1007\/s00198-017-4163-4","journal-title":"Osteoporos Int"},{"key":"1447_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbc.2023.105480","volume":"300","author":"Z Radvanyi","year":"2024","unstructured":"Radvanyi Z, Yoo EJ, Kandasamy P et al (2024) Extracellular sodium regulates fibroblast growth factor 23 (FGF23) formation. J Biol Chem 300:1\u201313. https:\/\/doi.org\/10.1016\/j.jbc.2023.105480","journal-title":"J Biol Chem"},{"key":"1447_CR146","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ecl.2022.11.002","volume":"52","author":"LE Cowen","year":"2023","unstructured":"Cowen LE, Hodak SP, Verbalis JG (2023) Age-Associated Abnormalities of Water Homeostasis. Endocrinol Metab Clin North Am 52:277\u2013293. https:\/\/doi.org\/10.1016\/j.ecl.2022.11.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1447_CR147","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1210\/jc.83.7.2275","volume":"83","author":"R Pivonello","year":"1998","unstructured":"Pivonello R, Colao A, Di Somma C et al (1998) Impairment of bone status in patients with central diabetes insipidus. J Clin Endocrinol Metab 83:2275\u20132280. https:\/\/doi.org\/10.1210\/jc.83.7.2275","journal-title":"J Clin Endocrinol Metab"},{"key":"1447_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22168551","volume":"22","author":"V Breuil","year":"2021","unstructured":"Breuil V, Trojani MC, Ez-Zoubir A (2021) Oxytocin and bone: review and perspectives. Int J Mol Sci 22:1\u201312. https:\/\/doi.org\/10.3390\/ijms22168551","journal-title":"Int J Mol Sci"},{"key":"1447_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1171732","volume":"14","author":"L Feixiang","year":"2023","unstructured":"Feixiang L, Yanchen F, Xiang L et al (2023) The mechanism of oxytocin and its receptors in regulating cells in bone metabolism. Front Pharmacol 14:1\u20137. https:\/\/doi.org\/10.3389\/fphar.2023.1171732","journal-title":"Front Pharmacol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01447-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:37:48Z","timestamp":1733895468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01447-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":149,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1447"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01447-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"10 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}